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HIGHLIGHTS 
 If frailty is a potential cardiovascular risk factor is poorly known.  
 In our work frailty was associated with higher prevalence and incidence of CVD.  
 Interventional studies are needed to confirm our findings.  
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ABSTRACT 
Frailty is common and associated with poorer outcomes in the elderly, but its role as potential 
cardiovascular disease (CVD) risk factor requires clarification. We thus aimed to meta-analytically 
evaluate the evidence of frailty and pre-frailty as risk factors for CVD. Two reviewers selected all 
studies comparing data about CVD prevalence or incidence rates between frail/pre-frail vs. robust. 
The association between frailty status and CVD in cross-sectional studies was explored by 
calculating and pooling crude and adjusted odds ratios (ORs) ±95% confidence intervals (CIs); the 
data from longitudinal studies were pooled using the adjusted hazard ratios (HRs). Eighteen cohorts 
with a total of 31,343 participants were meta-analyzed. Using estimates from 10 cross-sectional 
cohorts, both frailty and pre-frailty were associated with higher odds of CVD than robust 
participants. Longitudinal data were obtained from 6 prospective cohort studies. After a median 
follow-up of 4.4 years, we identified an increased risk for faster onset of any-type CVD in the frail 
(HR=1.70 [95%CI, 1.18-2.45]; I
2
=66%) and pre-frail (HR=1.23 [95%CI, 1.07-1.36]; I
2
=67%) vs. 
robust groups. Similar results were apparent for time to CVD mortality in the frail and pre-frail 
groups. In conclusion, frailty and pre-frailty constitute addressable and independent risk factors for 
CVD in older adults.  
 
Key words: frailty; cardiovascular disease; meta-analysis.  
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INTRODUCTION 
Frailty is typically defined as a state of “reduced physiological reserve and increased 
vulnerability for poor resolution of homeostasis after a stressor event”(Clegg et al., 2013) and is 
common among older adults, with an estimated prevalence of 10% in community-dwellers(Collard 
et al., 2012) and higher in people with cardiovascular diseases (CVD).(Afilalo, 2011; Finn and 
Green, 2015) Research addressing the relationship between frailty and CVD has suggested a bi-
directional relationship.(Afilalo et al., 2014) On the one hand, standard CVD risk factors, increased 
body weight, and physical inactivity in healthy midlife are each associated with old age 
frailty(Savela et al., 2013; Stenholm et al., 2014). Subclinical CVD is also associated with 
frailty.(Newman et al., 2001) CVDs are among the strongest contributors for frailty development in 
people with advanced age(Afilalo et al., 2014) , and the presence of frailty in older adults with CVD 
increases the risk of falls, institutionalization, repeated hospitalization and mortality.(Afilalo, 2011; 
Afilalo et al., 2014; Fukui et al., 2015) On the other hand,  since frailty and CVD share some 
common abnormalities, such as low-grade inflammation and insulin-resistance(Clegg et al., 2013), 
recent research proposed that frailty could be considered a potential CVD risk factor.(Phan et al., 
2008; von Haehling et al., 2013)  
This issue is highly relevant in geriatric medicine, because frailty and even more its 
precursor intermediate state (pre-frailty) might be reversible if appropriately treated(Ng et al., 
2015). The frailty phenotype is a syndromic condition requiring a comprehensive geriatric 
assessment for: 1) understanding which are the causes of the increased vulnerability, and 2) develop 
personalized plans of interventions (potentially covering physical and non-physical domains). The 
components of interventions for frailty may include physical exercise, nutrition, lifestyles, cognitive 
training, medication review(Santos-Eggimann et al., 2016), and specific therapies for underlining 
causes, like heart transplant for heart failure(Jha et al., 2016). Many of the interventions used for 
treating frailty (e.g. increasing physical activity levels and nutritional interventions) are also useful 
for decreasing CVD onset.(de Labra et al., 2015; Hanna and Wenger, 2005; Haskell, 2003) Whether 
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frailty and pre-frailty are risk factors for CVD is clinically important to the extent that the detection 
of these conditions in older subjects might offer a pertinent window for appropriate interventions 
that may delay the onset of CVD and consequently reduce disability, hospitalization and 
mortality.(Gary, 2012)   
The data regarding the relationship between frailty and future CVD have been not 
completely clear and, to the best of our knowledge, no meta-analysis has investigated if frailty 
status is associated with an increased risk of CVD and associated mortality. Therefore, the aim of 
the present study was to perform a systematic review and meta-analysis summarizing the evidence 
of frailty and pre-frailty as possible risk factors for CVD in older adults. The meta-analytical 
approach allows not only to overcome the limited evidence resulting from small studies, but also to 
provide a comprehensive quantitative review of available data and to assess the robustness as well 
as heterogeneity of the results, including their potential sources. We hypothesized that frail and pre-
frail individuals have a significantly increased risk of having and of developing CVD as well as 
related mortality, compared with robust older adults. 
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METHODS 
 This systematic review was conducted according to the Strengthening the Reporting 
of Observational Studies in Epidemiology [STROBE] criteria(von Elm et al., 2008) and the 
recommendations in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
[PRISMA] statement.(Liberati et al., 2009)
 
 
 Search strategy 
The published literature was searched using strategies created by a medical librarian for the 
concepts of frailty, risk, cardiovascular disease, and age 65 or older. The search strategies were 
established using a combination of standardized terms (free text or MeSH terms) and key words, 
and were implemented in Ovid Medline 1946-, Embase via Emabse.com 1947-, Cumulative Index 
of Nursing and Allied Health Literature 1937-, Cochrane Database of Systematic Reviews via 
Wiley, Cochrane Central Register of Controlled Trials via Wiley, and Database of Abstracts of 
Review via Wiley. To increase the chance of generating generalizable data, we conservatively 
excluded intervention studies, as randomized controlled trials generally have a whole host of 
exclusion criteria. Thus, articles indexed by the publication type of randomized or controlled trials 
were eliminated with the “NOT” Boolean operator. All searches were conducted from their 
inception until 12/31/2015 and without language restriction. All results were exported to EndNote 
for the removal of duplicates. The search strategy used in Pubmed is reported in eTable 1. A similar 
search (adapted to the requirements of each database) was run in the other databases.  Two 
investigators (NV, MS) independently conducted an electronic literature search and inconsistencies 
were resolved by consensus with a third author (VS).  
 References of articles included in the analysis and of others relevant to the topic were 
hand-searched to identify additional, potentially relevant publications. Conference abstracts were 
also considered, contacting the first or corresponding author for additional information at least 4 
times in 4 weeks.  
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 Study selection 
 We only considered studies that had a cross-sectional or longitudinal design;  
reported a multidimensional evaluation of the presence of frailty (such as using the criteria 
suggested by Fried(Fried et al., 2001), Rockwood(Rockwood et al., 2005) or Gill(Gill et al., 2002) 
as described in eTable 2); reported data on clinical CVD (self-reported, medical and/or hospital 
records, adjudicated disease diagnosis); and had a study population’s mean age ≥65 years. Studies 
were excluded if they reported CVD prevalence/incidence data only for one item included in the 
definition of frailty (e.g. low gait speed); investigated the role of frailty in people with CVD but 
focusing on non-CVD outcomes (e.g. overall mortality); reported data regarding frailty as 
consequence of a specific disease/condition (e.g. cancer); included only sub-clinical estimates of 
CVD; and focused on changes produced by specific interventions.   
 When data regarding CVD were available only for one item included in the 
definition of frailty (e.g. slow gait speed), the first and corresponding authors of each paper were 
contacted at least 4 times in 4 weeks to obtain further information about the other frailty domains.  
 
 Data extraction 
 To be included in the quantitative synthesis, studies had to provide data on odds or 
risk estimates (or data allowing us to compute these ourselves) for any-type CVD or for specific 
CVD (i.e., odds ratios [ORs] and hazard ratios [HRs] for cross-sectional and longitudinal studies, 
respectively), together with precision estimates (95% confidence interval [95%CI]) comparing 
frailty status conditions (taking robustness as reference group). Two authors (NV, EC) 
independently recorded data extracted from the selected studies into a standardized Microsoft Excel 
spreadsheet. Any disagreement was resolved by consensus with a third author (CC). The following 
information was extracted: i) study characteristics (e.g. sample size, demographics, country in 
which the study was performed); ii) study setting; iii) diagnostic criteria for frailty; iv) demographic 
characteristics (percentage of women and age) and risk factors for CVD prevalence (obesity, type 2 
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diabetes and hypertension) by frailty status; v) type and number of adjustments in the multivariate 
analyses; vi) follow-up period (only for longitudinal studies); vii) method of ascertainment of CVD.  
 When information on CVD was missing, study authors were contacted to obtain 
unpublished data. When two or more studies represented a cohort, all the articles were included 
contacting the first/corresponding author in order to have the most complete analyses available.  
These unpublished data were validated by the first or last authors of the studies from which these 
data were obtained. When raw data were shared with the main investigators of this project, these 
were independently analyzed by two authors of this meta-analysis (NV and EC). In addition to 
number of CVD by frailty status, we requested OR/HR estimates adjusted for the maximum number 
of the following covariates: age (as continuous variable), gender, obesity, type 2 diabetes, and 
hypertension. All the data were finally confirmed by the main investigator of each article. 
  
 Outcomes 
 The primary outcomes were the proportion and incidence of any-type of CVD 
according to frailty status. Secondary outcomes included the proportion and rate of onset: coronary 
heart disease (CHD), cerebrovascular disease (stroke and transient ischemic attack), heart failure, 
and peripheral vascular disease (PVD). In longitudinal studies the risk of CV mortality was also 
investigated.  
 
 Assessment of study quality 
 The Newcastle-Ottawa Scale (NOS)(Wells et al., 2012) was used to assess study 
quality. The NOS assigns a maximum of 9 points based on three quality parameters: selection, 
comparability, and outcome, with a cut-off of <5 being indicative of high risk of bias.(Wells et al., 
2012) NOS scores were initially assessed by two investigators (NV, CL), and discrepancies were 
addressed by a joint re-evaluation of the article with a third author (BS).  
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 Statistical analysis 
 Analyses were performed by two independent investigators (NV, EC) using Comprehensive 
Meta-Analysis (CMA) 3 (http://www.meta-analysis.com).  In primary analyses, pooled ORs (crude 
and fully adjusted) were calculated to synthesize data from cross-sectional studies, while pooled 
HRs (fully adjusted) were calculated for longitudinal studies. In secondary analyses, the same 
procedure was applied using specific CVD as outcome. When studies provided only estimates for 
specific CVDs, these were pooled with the others in both primary and secondary analyses. 
According to availability of data, the following comparisons were addressed: frail vs. robust; pre-
frail vs. robust; frail vs. pre-frail/robust. The random effects model was used to account for 
anticipated between-study heterogeneity.(DerSimonian and Laird, 1986)  
 Study heterogeneity was assessed using the chi-squared and I-squared statistics, assuming 
that a p≤0.05 for the former and a value ≥50% for the latter indicated a significant 
heterogeneity.(Higgins and Thompson, 2002) Whenever significant heterogeneity existed and ≥4 
studies were available, a meta-regression analysis was performed examining the following pre-
specified moderators: setting (community-dwelling vs. others), study quality (NOS score), number 
of adjustments (for adjusted analyses), follow-up period (for longitudinal investigations), frailty 
criteria (Fried’s vs. others), and outcome ascertainment (self-reported, medical and/or hospital 
records, adjudicated disease diagnosis). Strata analyses were conducted accordingly.  
 Publication bias was assessed by visually inspection of funnel plots and using the Egger bias 
test.(Egger et al., 1997)
 When ≥3 studies were available, we used the Duval and Tweedie 
nonparametric trim-and-fill method to account for potential publication bias. Based on the 
assumption that the effect sizes of all the studies are normally distributed around the center of a 
funnel plot, in the event of asymmetries, this procedure adjusts for the potential effect of 
unpublished (trimmed) studies.(Egger et al., 1997)  
 
RESULTS 
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 The search identified 8,953 non-duplicated, potentially eligible studies. After excluding 
8,897 papers on the grounds of a review of their titles and abstracts, 56 full-text articles were 
examined, and 21 articles(Avila-Funes et al., 2014; Blaum et al., 2005; Chaves, 2005; Danon-
Hersch et al., 2012; de Albuquerque Sousa et al., 2012; Dumurgier et al., 2009; Eichholzer et al., 
2012; Ekerstad et al., 2011; Frisoli et al., 2015; Green et al., 2012; Hajjar et al., 2009; Khan et al., 
2013; Lin et al., 2015; Moreira and Lourenco, 2013; Moretti et al., 2013; Polidoro et al., 2013; 
Ramsay et al., 2015; Ricci et al., 2014; Sanchis et al., 2014; Sergi et al., 2015; Wong et al., 2010) 
corresponding to 18 cohorts were finally included in our meta-analysis (Figure 1).  
 
 Study and patient characteristics 
 The 18 cohorts (Avila-Funes et al., 2014; Blaum et al., 2005; Chaves, 2005; Danon-Hersch 
et al., 2012; de Albuquerque Sousa et al., 2012; Dumurgier et al., 2009; Eichholzer et al., 2012; 
Ekerstad et al., 2011; Frisoli et al., 2015; Green et al., 2012; Lin et al., 2015; Moreira and Lourenco, 
2013; Moretti et al., 2013; Polidoro et al., 2013; Ramsay et al., 2015; Ricci et al., 2014; Sanchis et 
al., 2014; Sergi et al., 2015; Wong et al., 2010) included 4,469 frail participants out of 31,343 older 
subjects (eTable 3). Ten cohorts provided data on pre-frail (n=7,294) and robust (n=6,875) 
participants, while 8 (Chaves, 2005; Eichholzer et al., 2012; Ekerstad et al., 2011; Green et al., 
2012; Khan et al., 2013; Moretti et al., 2013; Polidoro et al., 2013; Ricci et al., 2014) compared frail 
(n=2,305) to pre-frail/robust participants (n=12,705). Meta-analyzed prevalence estimates according 
to frailty status are presented in Table 1. 
 All studies used a modified version of the definition proposed by Fried et al.(Fried et al., 
2001) for defining frailty, except three (two(Ekerstad et al., 2011; Polidoro et al., 2013) used the 
definition proposed by Rockwood et al.(Rockwood et al., 2005) and one(Khan et al., 2013) the 
Gill’s index(Gill et al., 2002)). Ten cohorts used a self-reported history for the diagnosis of 
CVD(Avila-Funes et al., 2014; Danon-Hersch et al., 2012; de Albuquerque Sousa et al., 2012; 
Dumurgier et al., 2009; Eichholzer et al., 2012; Hajjar et al., 2009; Lin et al., 2015; Moreira and 
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Lourenco, 2013; Polidoro et al., 2013; Ramsay et al., 2015; Ricci et al., 2014; Wong et al., 2010), 
five(Ekerstad et al., 2011; Green et al., 2012; Khan et al., 2013; Moretti et al., 2013; Sanchis et al., 
2014) medical/hospital records, three(Blaum et al., 2005; Chaves, 2005; Sergi et al., 2015) an 
adjudicated disease diagnosis and one(Frisoli et al., 2015) the criteria proposed by the American 
Heart Association.(Frisoli et al., 2015) The majority of the studies was conducted among 
community-dwellers and in Europe. The quality of the studies seems to be good, as shown by the 
NOS values. Frail participants appeared to be older and more frequently females than pre-frail, 
robust or pre-frail/robust participants. Regarding potential risk factors for CVD, frail participants 
showed a higher presence of obesity, type 2 diabetes and hypertension (eTable 3).  
 
 Cross-sectional findings 
 Using crude data from ten cohorts(Avila-Funes et al., 2014; Blaum et al., 2005; 
Danon-Hersch et al., 2012; de Albuquerque Sousa et al., 2012; Dumurgier et al., 2009; Frisoli et al., 
2015; Hajjar et al., 2009; Lin et al., 2015; Moreira and Lourenco, 2013; Ramsay et al., 2015; 
Sanchis et al., 2014; Wong et al., 2010) and taking 6,875 robust participants as the reference 
category, frail (n=1,561) and pre-frail (n=7,294) participants presented a significantly higher risk of 
any-type CVD: OR=3.44 [95%CI, 2.41-4.91] (p<0.001, I
2
=79%) and OR=1.59 [95%CI, 1.28-1.97] 
(p<0.001, I
2
=73%), respectively. These findings were confirmed when comparing frail vs. pre-
frail/robust participants (studies=15): OR=2.06 [95%CI, 1.51-2.81] (p<0.001, I
2
=89%). Similar 
associations were found for almost all specific CVDs (Table 2).  
 Table 3 shows the association between frailty and CVDs, adjusted for a median of 7 
(range: 1-8) potential confounders listed for each cohort (eTable 3). Taking robust participants as 
the reference, frailty (OR=2.85; 95%CI=2.29-3.53, p<0.001, I
2
=3%) and pre-frailty (OR=1.63; 
95%CI=1.39-1.91, p<0.001, I
2
=13%) were characterized by a higher risk of having any-type CVD 
(five studies, n=12,594)(Avila-Funes et al., 2014; Hajjar et al., 2009; Lin et al., 2015; Ramsay et al., 
2015; Sergi et al., 2015). The comparison of frail vs. pre-frail/robust participants in four cohorts, 
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n=6,517)(Hajjar et al., 2009; Lin et al., 2015; Ramsay et al., 2015; Sergi et al., 2015) led to similar 
results (OR=1.69; 95%CI=1.45-1.98, p<0.001, I
2
=0%). Again, the association between frailty and 
pre-frailty remained significant when analyzing specific CVDs (Table 2). While unadjusted ORs 
were associated with significant heterogeneity in individual study results, the analysis of adjusted 
estimates resulted in no heterogeneity for almost all outcomes. 
  
 Longitudinal findings 
 Six prospective cohort studies (Avila-Funes et al., 2014; Dumurgier et al., 2009; 
Eichholzer et al., 2012; Khan et al., 2013; Moretti et al., 2013; Sanchis et al., 2014; Sergi et al., 
2015) followed 18,307 participants (for a median of 4.4 (range: 1-11.4) years. Frail participants 
represented 16% of the baseline population (n=2,943), pre-frail 26% (n=4,875), robust 24% 
(n=4,488), while the remaining participants (n=6,669; 34%) were classified as pre-frail/robust 
(Table 1). With the exception of one study(Khan et al., 2013) that controlled for baseline CVD, 
analyses were based on participants free of CVD. 
Taking robust participants as the reference group and after adjusting for a median of 9 potential 
confounders (range: 7-13), frailty (HR=1.70 [95%CI, 1.18-2.45], p=0.004; I
2
=66%) (Figure 2a) 
and pre-frailty (HR=1.23 [95%CI, 1.07-1.36], p=0.009; I
2
=67%) (Figure 2b) were associated with 
significantly increased risk of shorter time to any-type CVD at follow-up. Similarly, frailty was 
associated with a significantly increased the risk of shorter time until CVD when compared to pre-
frail/robust participants (HR=1.56 [95%CI, 1.14-2.14], p=0.006; I
2
=74%) (Figure 2c).  
 Compared to robustness (Figure 2a-b), frailty increased the risk of CHD of 49% 
(95%CI, 1.10-2.04; p=0.01)(Avila-Funes et al., 2014; Sanchis et al., 2014; Sergi et al., 2015), of 
heart failure of 72% (95%CI, 1.19-2.45; p=0.004)(Khan et al., 2013; Sanchis et al., 2014; Sergi et 
al., 2015) and resulted in about a 4-fold increased risk of CV mortality (HR=3.89 [95%CI, 2.39-
6.34], p<0.001).(Sanchis et al., 2014; Sergi et al., 2015) Conversely, pre-frailty carried a significant 
higher risk of heart failure (HR=1.64 [95%CI, 1.06-2.55], p=0.026; I
2
=68%(Khan et al., 2013; 
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Sanchis et al., 2014; Sergi et al., 2015)) and CV mortality (HR=2.80 [95%CI, 1.83-4.28], p<0.001; 
I
2
=0%(Sanchis et al., 2014; Sergi et al., 2015)). Finally, frailty increased the risk of CHD(Avila-
Funes et al., 2014; Moretti et al., 2013; Sanchis et al., 2014; Sergi et al., 2015) (HR=1.49 [95%CI, 
1.00-2.19], p=0.045; I
2
=31%) as well as of CV mortality(Sanchis et al., 2014; Sergi et al., 2015) 
(HR=1.73 [95%CI, 1.17-2.54], p=0.006; I
2
=14%) compared to pre-frail/robust participants (Figure 
2c).  
 
 Meta-regression 
 The analysis of adjusted risk estimates from cross-sectional studies were not 
characterized by substantial heterogeneity, which was detected only for the risk of having heart 
failure and peripheral vascular disease. However, due to the limited number of studies (≤3) it was 
not possible to conduct a meta-regression to identify potential sources of heterogeneity.  
Conversely, analysis of longitudinal studies showed moderate heterogeneity for the incidence of 
any-type CVD in all investigated comparisons. Among the moderators considered, any-type CVD 
was especially higher in frail and in pre-frail individuals who were community dwelling compared 
to robust participants, while longer follow-up period increased the risk of any-type CVD in frail 
compared to pre-frail/robust individuals (eTable 4).  
 In a meta-analysis was restricted to the community setting (4 out of 5 studies), the 
pooling of risks for any-type CVD for frail (HR=1.38 [95%CI, 1.13-1.68], p=0.001; I
2
=0%) and 
pre-frail (HR=1.22 [95%CI, 1.09-1.35], p<0.001; I
2
=0%) participants resulted in no heterogeneity. 
However, when frail individuals were compared with pre-frail/robust individuals and studies were 
stratified by median duration of follow-up (4.4 years), only studies (n=3) with longer follow-up 
reported a significant association between frailty and incident of any-type CVD, with a reduction in 
heterogeneity (HR=1.22 [95%CI: 1.09-1.35], p<0.001; I
2
=0%).    
  
 Publication bias 
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 According to the visual inspection of funnel plots and using Egger’s test (see Tables 
2 and 3 for cross-sectional studies), no publication bias was evident for all primary and secondary 
outcomes included. A similar lack of publication bias was present for longitudinal studies. These 
findings were confirmed, using Eger’s regression test (p>0.05) and after imputing for potential 
unpublished studies (Duval and Tweedie trim-and-fill statistic). 
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DISCUSSION 
 In this meta-analysis including a total of 31,343 older participants, we found that 
frailty and pre-frailty were associated with increased risk of CVD. The increased risk of CVD was 
evident across both cross-sectional and prospective data analysis. Moreover, frailty was associated 
by a 3-fold higher risk of death due to CV causes. The association between frailty and pre-frailty 
with individual CVDs substantially confirmed those shown in the primary analyses. Frailty 
increased the risk of CHD, heart failure and CV mortality, while pre-frailty carried a significant 
higher risk of heart failure and CV mortality.  
 
The prevalence of frailty and pre-frailty were about 15% and 40%, respectively. 
Accordingly, in agreement with other surveys about this topic(Collard et al., 2012; Kojima, 2015), 
frailty and pre-frailty are highly prevalent conditions among older adults with important implication 
for health. Frail and pre-frail study participants seemed to have had an unfavorable metabolic 
profile, being characterized by higher rates of established CVD risk factors, like obesity, 
hypertension and type 2 diabetes, than robust participants. All the associations found between 
frailty conditions and CVD were independent of these potentially confounding CVD risk factors. 
This fact was particularly evident for cross-sectional data, as the synthesis of unadjusted and 
adjusted risk estimates yielded similar results (with significant reduction in heterogeneity in 
adjusted analyses), as well as when considering community-dwellers and longitudinal prospective 
investigations with longer follow-up. Pooled adjusted risks were characterized by limited to no 
heterogeneity in individual study results. Other factors than frailty, however, likely play a role in the 
relationship between frailty status and CVD.  
 
The association between frailty and CVD identified in this work does not allow a definitive 
causality assessment. Considering the results of prospective cohort studies, there is evidence strong 
suggestion for a cause-effect relationship between frailty and CVD, as analyses were substantially 
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based on participants free of clinical CVD at study entry. Cross-sectional data analyses may also  
support the hypothesis of an inverse relationship (i.e. CVD precedes the onset of frailty). 
Unfortunately, evidence on this topic from prospective studies is limited,(Stone et al., 2014)  even if 
some studies support the notion that subclinical CVD precedes frailty.(Newman et al., 2001; Savela 
et al., 2013; Stenholm et al., 2014; Strandberg et al., 2012)  It is thus likely that frail and pre-frail 
subjects had significant sub-clinical vascular and cardiac alterations,(Gharacholou et al., 2015; 
Katayama et al., 2015; Newman et al., 2001) which made the development of a clinical CVD more 
likely. Second, frail and pre-frail subjects seem to have several cellular and bio-humoral 
alterations(Zaslavsky et al., 2013) (e.g. higher oxidative stress and levels(Mulero et al., 2011), 
marked deoxyribonucleic acid damage(Ashar et al., 2015) and shorter telomere length(Zaslavsky et 
al., 2013))  that could contribute to the development of CVD.(Haycock et al., 2014; Heitzer et al., 
2001; MAHMOUDI et al., 2006) Third, frail people have elevated inflammatory markers (and 
consequently higher markers of thrombosis(Buckley et al., 2009)), which are known to play a role 
in the development of CVD.(Buckley et al., 2009) Finally, endocrine dysregulations present in frail 
and pre-frail people could play an additional role in the development of CVD since these people, for 
example, usually have lower IGF-1(Cappola et al., 2009) and sex hormones levels(Hyde et al., 
2010) compared to healthy controls and these factors may further increase CVD risk.(Corona et al., 
2011; Ren and Anversa, 2015)   
 
The implications for practice of present results may be substantial given the aging global 
population and rising levels of frailty. The importance of CVD in aging was recently discussed and 
the concept of frailty stressed.(Bell et al., 2015) Particularly, frailty and even more pre-frailty are 
reversible conditions if appropriately treated, thus reinforcing the importance of their assessment 
also by cardiologists. (Bell et al., 2015; Fried et al., 2001; Lee et al., 2014) Frailty, in fact, has 
surely more possibilities of being reversed compared to more advanced conditions typical of older 
people, such as disability. Very little is known if the treatment of frailty per se could be 
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preventative from a cardiovascular point of view. Even if drugs commonly used for the prevention 
of CVD may be poorly applicable in very frail older subjects(Granziera et al., 2015; Stone et al., 
2014), a recent study reported that strict adherence to guidelines for cardiovascular drugs could 
delay overall mortality in older adults affected by several chronic conditions.(Tinetti et al., 2015) 
For example, recent evidence suggests that the level of frailty among community-living older 
people does not interact with the efficacy of antihypertensive treatment.(Bulpitt et al., 2012) 
Conversely, the role of non-pharmacological interventions could represent a future topic of interest 
in the frail population. Reasons include evidence suggesting that comprehensive geriatric 
assessment seems to improve the early recognition of frailty syndromes. Therefore, the positive 
result of one of these tests should be followed by a comprehensive geriatric assessment of the 
individual for determining the underlying causes of frailty and plan personalized interventions. 
Regarding this topic. the application of several non-pharmacological interventions (e.g. physical 
exercise, dietary interventions, and reduction of unnecessary medications(Carraro et al., 2015; Sergi 
et al., 2015)) may delay and decrease the onset of CVD. (Bell et al., 2015) In particular, physical 
activity interventions might play a pivotal role in the prevention of both CVD and frailty.  Research 
is required to establish if physical activity interventions can prevent CVD onset among people with 
frailty and reverse frailty status.   
 
The findings of our meta-analysis must be considered within its limitations. First, the 
longitudinal studies included did not assess the transitions of participants across frailty status 
conditions, which could partly explain our results.(Lee et al., 2014) Second, frailty was evaluated 
mainly through the criteria suggested by Fried(Fried et al., 2001), but this definition suffers from 
some limitations, like not considering cognitive aspects that are, on the contrary, relevant for the 
assessment of frailty in the elderly.(Kuller et al., 2016) The definitions are also not taking into 
account specific demographic and clinical variables that may define a syndrome of “biological 
frailty”. For example, work performed by some of us has identified age 65 and older, increased 
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blood urea nitrogen, and decreased haemoglobin and albumin levels as independent predictors for 
the large number of significant medical deteriorations occurring in patients hospitalized for 
psychiatric conditions.(Manu et al., 2012) In this large cohort, the medical deteriorations became 
manifest frequently as falls or febrile syndromes, and required often admissions to medical units. It 
is reasonable then to assume that biologically frail elderly patients receive a higher level of medical 
attention, leading to the discovery of pre-existent cardiovascular conditions prevalent in this age 
group. 
The published studies included in our analysis have usually adopted modified versions of the 
tools originally suggested by Fried(Fried et al., 2001), and this could introduce a bias in our 
results.(Theou et al., 2015) However, the heterogeneity of pooled estimates was low, which could 
be considered a major point of strength of our study. The inclusion of different criteria for assessing 
frailty seems to poorly affect our results in terms of heterogeneity suggesting that, independently 
from the definition (and the tool used in the assessment), frailty is associated with a higher risk of 
CVD in the elderly. Furthermore, in ten cohorts only self-reported diagnosis of CVD was 
considered and this could have introduced another bias since a remarkable percentage of CVD in 
the elderly is asymptomatic.(Cefalu CA, Burris, 1996) Finally, due to the limited number of studies 
reporting detailed information, we were unable to assess if differences in the prevalence of specific 
CVD risk factors significantly moderated the outcomes. Despite these limitations, clear strengths of 
this meta-analysis include the large number of cohorts and participants analyzed, the relatively long 
follow-up duration of the longitudinal investigations, and the large number of relevant statistical 
adjustments and outcomes considered.  
In conclusion, frailty and pre-frailty have a close connection with CVD and they constitute 
modifiable risk factors for CVD in older people. Since CVD events represent an important source of 
disability and mortality, our meta-analysis confirms the importance of screening for frailty status 
conditions. This should apply to both subjects/patients with or without and increased CV risk. 
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Future studies are required to evaluate if addressing frailty and pre-frailty and their underlying 
causes could positively influence CV outcomes. 
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FIGURE LEGEND 
Figure 1. PRISMA flow-chart 
 
Figure 2. Meta-analysis and pooled fully-adjusted HRs of CVDs and CV mortality in frail and 
pre-frail participants from prospective cohort studies: Forrest plot A, frail vs. robust; Forrest 
plot B, pre-frail vs. robust; Forrest plot C, frail vs. pre-frail/robust.  
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Table 1. Meta-analysed prevalence of frailty and pre-frailty in the studies included.  
Cross-sectional studies Longitudinal studies 
Cohorts 
(population) 
Frail 
% (95%CI) 
Pre-frail 
% (95%CI) 
Cohorts 
(population) 
Frail 
% (95%CI) 
Pre-frail 
% (95%CI) 
18 (31,343) 17.9 (11.4-27.0) -- 7 (18,970) 15.9 (6.8-32.9) -- 
10 (16,400) 12.0 (8.3-17.0) 43.7 (38.7-48.8) 4 (10,278) 12.7 (6.9-22.1) 42.3 (36.6-48.2) 
 
Notes:  
Prevalence is reported as percentage with 95% confidence intervals. The first row is referred to the studies including frail vs. pre-frail and/or robust; 
the second to the studies including only studies reporting data on frail vs. pre-frail vs. robust.   
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Table 2. Meta-analysis of cross-sectional studies with publication bias assessment 
Analysis 
Number 
of 
studies 
Number 
participants 
Meta-analysis Heterogeneity Publication bias 
  
1
st
 
group 
2
nd
 
group 
OR 95% CI P-value I
2
 
Egger bias & 
p-value 
Adjusted risk 
estimates*  
(95% CI) 
CVD 
Frail vs. robust 10 1561 6875 3.44 2.41 4.91 <0.001 79 1.66; 0.42 4.15 (2.78 to 6.21) 
Pre-frail vs. robust 10 7294 6875 1.59 1.28 1.97 <0.001 73 -2.10; 0.18 1.65 (1.32 to 2.06) 
Frail vs. pre-frail /robust 15 3866 21607 2.06 1.51 2.81 <0.001 89 1.38; 0.41 Unchanged 
CHD 
Frail vs. robust 8 1363 6155 2.79 2.20 3.35 <0.001 34 0.75; 0.67 Unchanged 
Pre-frail vs. robust 8 6436 6155 1.93 1.14 3.26 0.01 93 -3.03; 0.51 2.23 (1.40 to 3.36) 
Frail vs. pre-frail /robust 13 3574 19453 1.44 1.06 1.97 0.02 86 0.42; 0.80 Unchanged 
Stroke + TIA 
Frail vs. robust 9 1525 6354 4.58 2.56 8.20 <0.001 79 0.29; 0.91 5.70 (3.01 to 10.82) 
Pre-frail vs. robust 9 6903 6354 2.11 1.59 2.83 <0.001 37 -1.78; 0.10 2.31 (1.65 to 3.24) 
Frail vs. pre-frail /robust 13 2311 18719 2.83 2.00 3.99 <0.001 76 -0.52; 0.72 3.29 (2.31 to 4.70) 
Heart failure 
Frail vs. robust 5 789 2365 4.99 1.93 12.94 0.001 88 -2.62; 0.58 6.95 (2.68 to 17.98) 
Pre-frail vs. robust 5 3098 2365 1.49 0.62 3.59 0.38 88 -4.37; 0.28 1.95 (0.84 to 4.51) 
Frail vs. pre-frail /robust 7 1047 5656 3.25 1.89 5.60 <0.001 83 -2.08; 0.53 2.37 (1.33 to 4.25) 
PVD 
Frail vs. robust 6 972 2499 3.72 2.55 5.41 <0.001 37 1.17; 0.28 2.95 (1.95 to 4.47) 
Pre-frail vs. robust 6 3399 2499 2.00 1.37 2.94 <0.001 54 0.51; 0.65 1.83 (1.24 to 2.70) 
Frail vs. pre-frail /robust 9 2622 7539 1.78 1.14 2.71 <0.001 83 0.73; 0.75 1.43 (0.93 to 2.20) 
Bold values represent significant results, as p-value <0.05 
Abbreviations: CHD: coronary heart disease; CI: confidence intervals; CVD, cardiovascular diseases; OR, odds ratio; PVD: peripheral vascular 
disease; TIA, transient ischemic attack.  
* Test for publication bias: Duval and Tweedie nonparametric trim-and-fill procedure 
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Table 3. Adjusted odds ratios of cross-sectional studies included with publication bias assessment.  
Analysis 
Number 
of 
studies 
Meta-analysis Heterogeneity Publication bias 
  OR 95% CI P-value I
2
 
Egger bias & 
p-value 
Adjusted risk estimates* 
(95% CI) 
CVD 
Frail vs. robust 5 2.85 2.29 3.53 <0.001 3 2.19; 0.26 Unchanged 
Pre-frail vs. robust 5 1.63 1.39 1.91 <0.001 13 2.41; 0.23 1.54 (1.29 to 1.81) 
Frail vs. pre-frail /robust 4 1.69 1.45 1.98 <0.001 0 0.78; 0.31 Unchanged 
CHD 
Frail vs. robust 4 2.86 2.20 3.71 <0.001 0 5.24; 0.11 2.69 (2.11 to 3.43) 
Pre-frail vs. robust 4 1.58 1.32 1.88 <0.001 0 1.53; 0.55 Unchanged 
Frail vs. pre-frail /robust 3 1.43 0.90 2.29 0.13 30 0.66; 0.73 Unchanged 
Stroke + TIA 
Frail vs. robust 4 3.38 2.37 4.81 <0.001 0 0.20; 0.94 3.20 (2.28 to 4.47) 
Pre-frail vs. robust 4 1.98 1.53 2.57 <0.001 0 3.57; 0.48 Unchanged 
Frail vs. pre-frail /robust 2 2.20 1.62 2.99 <0.001 0   
Heart failure 
Frail vs. robust 3 8.76 2.76 27.83 <0.001 72 3.14; 0.17 3.83 (1.31 to 11.24) 
Pre-frail vs. robust 3 1.89 1.03 3.47 0.03 29 1.83; 0.19 1.52 (0.86 to 2.69) 
Frail vs. pre-frail /robust 2 2.20 1.62 2.99 <0.001 0   
PVD 
Frail vs. robust 3 3.45 1.79 6.64 <0.001 72 3.86; 0.05 Unchanged 
Pre-frail vs. robust 2 2.45 0.77 7.84 0.13 80   
Frail vs. pre-frail /robust 0        
Bold values represent significant results, as p-value <0.05 
Abbreviations: CHD: coronary heart disease; CI: confidence intervals; CVD, cardiovascular diseases; OR, odds ratio; PVD: peripheral vascular 
disease; TIA, transient ischemic attack.  
* Test for publication bias: Duval and Tweedie nonparametric trim-and-fill procedure 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching 
( n =  10258 ) 
Sc
re
en
in
g 
In
cl
ud
ed
 
E
lig
ib
ili
ty
 
Id
en
tif
ic
at
io
n 
Additional records identified 
through other sources 
( n =  0 ) 
Records after duplicates removed 
( n =8953 ) 
Records screened 
( n = 8953 )
Records excluded (not pertinent)
(n = 8897 ) 
Full-text articles 
assessed for eligibility 
( n =  56 ) 
Full-text articles excluded, with 
reasons 
( n =  35 ) 
No data about CVD (n=12) 
All participants with CVD (n=7) 
Reviews (n=7) 
Only gait speed (n=5) 
No data about frailty (n=4) 
Studies included in 
qualitative synthesis 
( n = 21)
Studies included in 
quantitative synthesis 
(meta-analysis) 
( n = 21 ) 
(18 cohorts) 
3-City study. 2014 
Khan. 2013 
Sanchis. 2014 
Sergi. 2015 
1.47 
1.88 
3.40 
1.26 
1.70 
1.03 
1.02 
1.80 
0.98 
1.18 
2.10 
3.47 
6.41 
1.63 
2.45 
2.12 
2.02 
3.78 
1.77 
2.86 
0.03 
0.04 
0.000 
0.08 
0.004 
Any-type CVD 
3-City study. 2014 
Sanchis. 2014 
Sergi. 2015 
1.37 
1.60 
1.60 
1.49 
0.86 
0.79 
0.96 
1.01 
2.18 
3.30 
2.66 
2.04 
1.33 
1.30 
1.81 
2.56 
0.19 
0.19 
0.07 
0.01 
3-City study. 2014 
Sergi. 2015 
1.37 
1.44 
1.386 
0.79 
0.52 
0.852 
2.38 
4.00 
2.254 
0.27 
0.48 
0.19 
Khan. 2013 
Sanchis. 2014 
Sergi. 2015 
1.88 
3.20 
1.44 
1.72 
1.02 
1.27 
1.12 
1.185 
3.47 
8.04 
1.86 
2.50 
2.02 
2.47 
2.82 
2.85 
0.04 
0.01 
0.005 
0.004 
Sanchis. 2014 
Sergi. 2015 
4.80 
3.41 
3.89 
2.20 
1.829 
2.393 
10.49 
6.36 
6.34 
0.000 
0.000 
0.000 
1.12 
0.70 
1.31 
3.93 
3.86 
5.47 
TOTAL (I2=66%; p=0.034) 
CV mortality 
Coronary heart disease 
Stroke or TIA 
Heart failure 
Hazard ratio and 95% CI 
Hazard  Lower  Upper  
ratio limit limit Z-Value p-Value 
0.1 0.2 0.5 1 2 5 10 
TOTAL (I2=0%; p=0.89) 
TOTAL (I2=0%; p=0.93) 
TOTAL (I2=35%; p=0.22) 
TOTAL (I2=0%; p=0.50) 
A Pooled risk estimates for frail vs. robust participants 
Hazard ratio and 95% CI 
Hazard  Lower  Upper  
ratio limit limit Z-Value p-Value 
0.1 0.2 0.5 1 2 5 10 
3-City study. 2014 
Khan. 2013 
Sanchis. 2014 
Sergi. 2015 
1.13 
1.36 
3.10 
1.21 
1.32 
0.93 
1.08 
1.61 
1.04 
1.07 
1.38 
1.71 
5.95 
1.40 
1.63 
1.21 
2.62 
3.40 
2.51 
2.63 
0.23 
0.009 
0.001 
0.01 
0.009 
3-City study. 2014 
Sanchis. 2014 
Sergi. 2015 
1.04 
1.50 
1.45 
1.01 
0.82 
0.71 
0.59 
0.88 
1.33 
3.16 
3.56 
1.37 
0.32 
1.07 
0.81 
0.81 
0.75 
0.29 
0.42 
0.42 
3-City study. 2014 
Sergi. 2015 
1.19 
0.93 
1.14 
0.87 
0.48 
0.85 
1.63 
1.80 
1.51 
1.08 
-0.22 
0.88 
0.28 
0.83 
0.38 
Khan. 2013 
Sanchis. 2014 
Sergi. 2015 
1.36 
4.40 
1.35 
1.64 
1.08 
1.79 
0.92 
1.06 
1.71 
10.83 
2.00 
2.55 
2.62 
3.22 
1.52 
2.22 
0.009 
0.001 
0.13 
0.03 
Sanchis. 2014 
Sergi. 2015 
2.90 
2.77 
2.80 
1.22 
1.705 
1.834 
6.90 
4.500 
4.277 
2.41 
4.12 
4.77 
Any-type CVD 
TOTAL (I2=67%; p=0.03) 
CV mortality 
Coronary heart disease 
Stroke or TIA 
Heart failure 
TOTAL (I2=0%; p=0.54) 
TOTAL (I2=0%; p=0.51) 
TOTAL (I2=68%; p=0.044) 
TOTAL (I2=0%; p=0.93) 
B Pooled risk estimates for pre-frail vs. robust participants 
0.02 
0.000 
0.000 
Hazard ratio and 95% CI 
Hazard  Lower  Upper  
ratio limit limit Z-Value p-Value 
0.1 0.2 0.5 1 2 5 10 
3-City study. 2014 
Eicholzer. 2014 
Moretti. 2013 
Sanchis. 2014 
Sergi. 2015 
1.370 
2.130 
2.600 
1.700 
1.090 
1.562 
0.979 
1.599 
0.867 
1.106 
0.877 
1.137 
1.918 
2.838 
7.800 
2.614 
1.355 
2.146 
1.835 
5.165 
1.705 
2.418 
0.776 
2.750 
0.067 
0.000 
0.088 
0.016 
0.438 
0.006 
3-City study. 2014 
Moretti. 2013 
Sanchis. 2014 
Sergi. 2015 
1.34 
3.40 
1.30 
1.10 
1.49 
0.86 
1.42 
0.72 
0.49 
1.01 
2.09 
8.13 
2.36 
2.46 
2.19 
1.29 
2.75 
0.87 
0.23 
2.00 
0.20 
0.006 
0.39 
0.82 
0.05 
3-City study. 2014 
Sanchis. 2014 
Sergi. 2015 
1.24 
1.70 
1.52 
1.31 
0.74 
0.06 
0.61 
0.84 
2.08 
48.98 
3.76 
2.05 
0.81 
0.31 
0.91 
1.19 
0.42 
0.76 
0.37 
0.24 
Moretti. 2013 
Sanchis. 2014 
Sergi. 2015 
1.20 
1.20 
1.00 
1.05 
0.54 
0.60 
0.72 
0.794 
2.68 
2.40 
1.40 
1.40 
0.44 
0.52 
0.000 
0.37 
0.66 
0.61 
1.00 
0.71 
Sanchis. 2014 
Sergi. 2015 
2.20 
1.40 
1.73 
1.24 
0.94 
1.17 
3.92 
2.31 
2.54 
2.68 
1.67 
2.77 
0.007 
0.01 
0.006 
Any-type CVD 
TOTAL (I2=74%; p=0.004) 
CV mortality 
Coronary heart disease 
Stroke or TIA 
Heart failure 
TOTAL (I2=31%; p=0.22) 
TOTAL (I2=0%; p=0.92) 
TOTAL (I2=0%; p=0.85) 
TOTAL (I2=14%; p=0.28) 
C Pooled risk estimates for frail vs. pre-frail/robust participants 
